It is the factual basis of the FTCs September 2024 lawsuit against the Big Three PBMs, which alleged that insulin products with lower list prices and therefore smaller rebates available were systematically excluded from formularies in favor of higher-list-price alternatives that generated larger rebate payments to PBMs and their affiliated GPOs
A: Section 3(d) of the Indian Patents Act prohibits patenting of new forms of previously known pharmaceutical substances, including salts, esters, polymorphs, and crystal forms, unless they show significantly enhanced therapeutic efficacy
Most reports involved men aged 4060 with T2D being the main indication of use (43.9%)
According to publicly available records, Sermorelin was previously FDA-approved (marketed as Geref) for diagnostic use and for certain pediatric growth hormone applications
2-month minimum commitment and higher-dose pricing increases are not clearly mentioned before intake
acetyl L-carnitine hydrochloride, vegetable capsule (coating agent: hydroxypropyl methyl cellulose), anti-caking agents: silicon dioxide, magnesium salts of fatty acids